Literature DB >> 9717420

Biliopancreatic diversion with duodenal switch.

P Marceau1, F S Hould, S Simard, S Lebel, R A Bourque, M Potvin, S Biron.   

Abstract

In 1990 Scopinaro's technique of biliopancreatic diversion with distal gastrectomy (DG) and gastroileostomy was modified. A sleeve gastrectomy with duodenal switch (DS) was used instead of the distal gastrectomy; and the length of the common channel was made 100 cm instead of 50 cm. A questionnaire and a prescription for blood work were sent to 252 patients who underwent DG a mean 8.3 years ago (range 6-13 years) and 465 patients who underwent DS 4.1 years ago (range 1.7-6.0 years). The questionnaire response rate was 93%, and laboratory work was completed for 65% of both groups. The mean weight loss after DG was 37 +/- 21 kg and after DS 46 +/- 20 kg. There were fewer side effects after DS: The number of daily stools was lower (p < 0.0002), as was the prevalence of diarrhea (p < 0.01), vomiting (p < 0.001), and bone pain (p < 0.001). Greater benefits related to several aspects of life were reported after DS than DG (p < 0.0001). The mean serum levels of ferritin, calcium, and vitamin A were higher (p < 0.001), and parathyroid hormone was lower. The yearly revision rate for excessive malabsorption was 1.7% per year after DG and 0.1% per year after DS. The two procedures were equally efficient for treating co-morbid conditions such as diabetes, hypertension, and hypercholesterolemia. Biliopancreatic diversion with sleeve gastrectomy/duodenal switch and a 100-cm common limb was shown to produce greater weight loss with fewer side effects.

Entities:  

Mesh:

Year:  1998        PMID: 9717420     DOI: 10.1007/s002689900498

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  153 in total

Review 1.  The neurohormonal regulation of energy intake in relation to bariatric surgery for obesity.

Authors:  Christopher N Ochner; Charlisa Gibson; Susan Carnell; Carl Dambkowski; Allan Geliebter
Journal:  Physiol Behav       Date:  2010-05-08

2.  Laparoscopic vs. open biliopancreatic diversion with duodenal switch: a comparative study.

Authors:  Won-Woo Kim; Michel Gagner; Subhash Kini; William B Inabnet; Terri Quinn; Daniel Herron; Alfons Pomp
Journal:  J Gastrointest Surg       Date:  2003 May-Jun       Impact factor: 3.452

3.  Open and laparoscopic surgical modalities for the management of obesity.

Authors:  Philip R Schauer
Journal:  J Gastrointest Surg       Date:  2003 May-Jun       Impact factor: 3.452

Review 4.  Obesity surgery: pros and cons.

Authors:  J A Waitman; L J Aronne
Journal:  J Endocrinol Invest       Date:  2002-11       Impact factor: 4.256

5.  Biliopancreatic diversion with duodenal switch vs. gastric bypass for severe obesity.

Authors:  Daniel M Herron
Journal:  J Gastrointest Surg       Date:  2004 May-Jun       Impact factor: 3.452

Review 6.  [Metabolic surgery].

Authors:  C Jurowich; C T Germer; F Seyfried; A Thalheimer
Journal:  Chirurg       Date:  2012-06       Impact factor: 0.955

7.  Long-term results of biliopancreatic diversion with or without gastric preservation for morbid obesity.

Authors:  Nicola Crea; Giacomo Pata; Ernesto Di Betta; Francesco Greco; Claudio Casella; Antonio Vilardi; Francesco Mittempergher
Journal:  Obes Surg       Date:  2011-02       Impact factor: 4.129

8.  Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease.

Authors:  Francesco Rubino; Jacques Marescaux
Journal:  Ann Surg       Date:  2004-01       Impact factor: 12.969

Review 9.  Biliopancreatic diversion in the surgical treatment of morbid obesity.

Authors:  Robrecht H G G Van Hee
Journal:  World J Surg       Date:  2004-04-19       Impact factor: 3.352

10.  Staple-line reinforcement with bovine pericardium in laparoscopic sleeve gastrectomy: experimental comparative study in pigs.

Authors:  Ahmad Assalia; Kazuki Ueda; Ronald Matteotti; Federico Cuenca-Abente; Tomasz Rogula; Michel Gagner
Journal:  Obes Surg       Date:  2007-02       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.